$121.18
3.28% day before yesterday
NYSE, Mar 14, 09:10 pm CET
ISIN
US00846U1016
Symbol
A
Sector
Industry

Agilent Technologies Stock price

$121.18
-13.49 10.02% 1M
-17.13 12.39% 6M
-13.16 9.80% YTD
-24.03 16.55% 1Y
-6.40 5.02% 3Y
+57.05 88.96% 5Y
+79.37 189.84% 10Y
NYSE, Closing price Fri, Mar 14 2025
+3.85 3.28%
ISIN
US00846U1016
Symbol
A
Sector
Industry

Key metrics

Market capitalization $34.55b
Enterprise Value $36.44b
P/E (TTM) P/E ratio 27.85
EV/FCF (TTM) EV/FCF 27.78
EV/Sales (TTM) EV/Sales 5.58
P/S ratio (TTM) P/S ratio 5.29
P/B ratio (TTM) P/B ratio 5.73
Dividend yield 0.78%
Last dividend (FY24) $0.94
Revenue growth (TTM) Revenue growth -3.00%
Revenue (TTM) Revenue $6.53b
EBIT (operating result TTM) EBIT $1.59b
Free Cash Flow (TTM) Free Cash Flow $1.31b
Cash position $1.47b
EPS (TTM) EPS $4.35
P/E forward 23.85
P/S forward 5.13
EV/Sales forward 5.41
Short interest 1.36%
Show more

Is Agilent Technologies a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,808 stocks worldwide.

Agilent Technologies Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Agilent Technologies forecast:

8x Buy
40%
12x Hold
60%

Analyst Opinions

20 Analysts have issued a Agilent Technologies forecast:

Buy
40%
Hold
60%

Financial data from Agilent Technologies

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jan '25
+/-
%
6,533 6,533
3% 3%
100%
- Direct Costs 2,983 2,983
3% 3%
46%
3,550 3,550
3% 3%
54%
- Selling and Administrative Expenses 1,254 1,254
5% 5%
19%
- Research and Development Expense 439 439
8% 8%
7%
1,857 1,857
1% 1%
28%
- Depreciation and Amortization 267 267
0% 0%
4%
EBIT (Operating Income) EBIT 1,590 1,590
1% 1%
24%
Net Profit 1,259 1,259
2% 2%
19%

In millions USD.

Don't miss a Thing! We will send you all news about Agilent Technologies directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Agilent Technologies Stock News

Neutral
Business Wire
5 days ago
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications ...
Neutral
Seeking Alpha
11 days ago
Agilent Technologies, Inc. (NYSE:A ) TD Cowen 45th Annual Healthcare Conference Call March 4, 2025 9:50 AM ET Company Participants Padraig McDonnell - Chief Executive Officer Bob McMahon - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen Daniel Brennan Alright, good. I guess we'll start in a minute or two early here, great day two of the TD Cowen Global Healthcare ...
Neutral
Seeking Alpha
15 days ago
Agilent Technologies, a leader in life sciences and diagnostics, has a market cap of $38B and a 10-year CAGR of 13.6%. Key financial metrics: consistent revenue growth, stable gross profit margin above 50%, and a robust return on invested capital, despite some fluctuations. The stock fell too far after its recent earnings report, making it too good to pass up at its current level.
More Agilent Technologies News

Company Profile

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Head office United States
CEO Padraig Mcdonnell
Employees 17,900
Founded 1999
Website www.agilent.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today